Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05155085 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
A Phase 2 study, sponsored by Allakos.
- Terminated
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT05155085 is a Phase 2 study that was terminated before completion, run by Allakos. The registered enrollment target is 131 participants.
The verdict
NCT05155085, a Phase 2 study, was terminated before completion, sponsored by Allakos.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with moderate-to-severe AD inadequately controlled by topical treatments. Subjects who complete the randomized, double-blind, placebo-controlled treatment period may have the option to enroll in an open-label extension period and receive up to 7 doses of subcutaneous lirentelimab.
Interventions
- OTHER Placebo
- DRUG AK002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2022-06-27 |
| Est. Completion | 2024-04-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05155085
The ClinicalTrials.gov registry entry for NCT05155085 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allakos, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05155085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05155085 about?
NCT05155085 is a clinical study titled "A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis". This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with moderate-to-severe AD inadequately controlled by topical treatments. Subjects who compl...
What is the current status of trial NCT05155085?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2022-06-27. Estimated completion is 2024-04-17.
What interventions are being tested in trial NCT05155085?
The interventions under investigation include: Placebo (OTHER), AK002 (DRUG).
Who is sponsoring clinical trial NCT05155085?
This trial is sponsored by Allakos, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.